Chief Business Officer

Mr. Agarwal has over 20 years of experience in corporate development, financing, strategy and commercial operations. His experience includes assessment, diligence, negotiation, contracts and alliances across a range of transactions such as M&A, regional and global product licensing, research and clinical collaborations, IP licensing, commercial distribution and manufacturing agreements.

Prior to joining ReCode Therapeutics in 2020, Mr. Agarwal was Vice President of Corporate Development at Forty Seven, Inc (acquired by Gilead). Before Forty Seven, he held the roles of VP, Business Development at Revance, Senior Director, Corporate Development and Strategy at Anacor (acquired by Pfizer), and Director, Global Business Development and Licensing at Forest Pharmaceuticals (acquired by Allergan, now AbbVie). He has also held commercial strategy, brand marketing, and portfolio management roles at MedImmune (acquired by Astra Zeneca), GlaxoSmithKline and Genentech.

Mukul received his M.B.A. from Carnegie Mellon University, M.S. from Ohio State University, and B. Tech. from Indian Institute of Technology, Delhi.